{"id":"tp-56239","type":"article-newspaper","title":"SERB Deal Lifts Hansa Biopharma's Q3 Revenue to SEK 143 Million","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/56239","datePublished":"2026-11-13T03:31:35.000Z","dateModified":"2026-11-13T03:31:35.000Z","language":"en","abstract":"License revenue included part of a €110 million upfront payment for Idefirix rights in Europe and the MENA region. Basic and diluted earnings per share were negative SEK 1.75.","section":"Business","references":[]}